Professor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Michael A. Caligiuri, MD
|
|
Give Review
Michael Caligiuri works in the field of Oncology. He researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is a one of the best medicals schools. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine He received awards:"Fellow (FACP)" and "Elected Member". Dr. Michael A. Caligiuri is a published physician. He published 102 publications, including: 'Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts.'
Publications
- Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment.
- NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin are Enhanced by Cytokines.
- Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia.
- The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
- Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.
- The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
- Transcription factor foxo1 is a negative regulator of natural killer cell maturation and function.
- Granzyme B Expression Is Enhanced in Human Monocytes by TLR8 Agonists and Contributes to Antibody-Dependent Cellular Cytotoxicity.
- Promoter-specific hypomethylation is associated with overexpression of PLS3, GATA6 and TWIST1 in Sezary syndrome.
- The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development.
- PTEN is a negative regulator of NK cell cytolytic function.
- Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
- Human Leukocyte Antigen Type and Posttransplant Lymphoproliferative Disorder.
- Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.
- The Natural Product Phyllanthusmin C Enhances IFN-γ Production by Human NK Cells through Upregulation of TLR-Mediated NF-κB Signaling.
- Preclinical evaluation of Echinomycin: therapeutic efficacy in relapsed acute myeloid leukemia without adverse effects on host hematopoietic stem cells.
- Role of Cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.
- The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells.
- Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects.
- Molecular pathways: interleukin-15 signaling in health and in cancer.
- Human natural killer cell development in secondary lymphoid tissues.
- Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia witha sole trisomy 8.
- Cancer Immunology at the Crossroads: Killer immunoglobulin-like receptors and tumor immunity.
- Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808.
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
- Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease.
- Location and cellular stages of natural killer cell development.
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance In Vitro and In Vivo anti-tumor activity against human multiple myeloma.
- Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes.
- Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients.
- Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.
- Towards personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.
- MicroRNAs activate natural killer cells through toll-like receptor signaling.
- Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative S...
- Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia.
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Proper...
- Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells.
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a po...
- NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
- Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia.
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
- inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
- Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation.
- Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates expression of the anti-leukemic microRNA-181a in acute myeloid leukemia.
- Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
- MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response.
- RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA E...
- The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.
- Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
- Mll-partial tandem duplication and Flt3-internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
- miR-3151 interplays with its host gene BAALC and independently impacts on outcome of patients with cytogenetically normal acute myeloid leukemia.
- Regulation of acute graft-versus-host disease by microRNA-155.
- Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically-abnorma...
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN "favorable" genetic category.
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
- Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
- Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetical...
- TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study.
- IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells.
- NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.
- The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells.
- Innate or adaptive immunity? The example of natural killer cells.
- The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis.
- LyGDI, a Novel SHIP-Interacting Protein, Is a Negative Regulator of Fc?R-Mediated Phagocytosis.
- Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal ac...
- PRDM1/Blimp-1 controls effector cytokine production in human NK cells.
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogen...
- Immature NK cells, capable of producing IL-22, are present in human uterine mucosa.
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
- Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue.
- IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
- In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis.
- miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.
- CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
- Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression...
- CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.
- Purification of human NK cell developmental intermediates from lymph nodes and tonsils.
- CD94 defines phenotypically and functionally distinct mouse NK cell subsets.
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
- Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myelo...
- TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.
- A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22.
- Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells.
- The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.
- Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-ris...
- Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Le...
- Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
- Natural killer cells in innate immunity and cancer.
- The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.
- TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.
- DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
- Human natural killer cells.
- IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic ly...
- MicroRNA expression in cytogenetically normal acute myeloid leukemia.
- Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts.
Schools
Stanford University School Of Medicine
BrighamWomens Hospital
Dana Farber Canc Institute
Ohio State39s Comprehensive Cancer Center Director
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- Fellow (FACP)
- Elected Member
Education
-
Brigham and Women's Hospital -
Stanford University School of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Robert Wesolowski, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Erin M. Olson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brent C. Behrens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samantha M. Jaglowski, MD
This Doctor is OpenDoctor Recommended.
|